CVE-2021-25680

Public Exploit

Description

The AdTran Personal Phone Manager software is vulnerable to multiple reflected cross-site scripting (XSS) issues. These issues impact at minimum versions 10.8.1 and below but potentially impact later versions as well since they have not previously been disclosed. Only version 10.8.1 was able to be confirmed during primary research. NOTE: The affected appliances NetVanta 7060 and NetVanta 7100 are considered End of Life and as such this issue will not be patched

Category

6.1
CVSS
Severity: Medium
CVSS 3.1 •
CVSS 2.0 •
EPSS 1.74% Top 20%
Vendor Advisory adtran.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://adtran.com vendor advisory
https://github.com/3ndG4me/AdTran-Personal-Phone-Manager-Vulns/blob/main/CVE-2021-25680.md third party advisory exploit
http://packetstormsecurity.com/files/162269/Adtran-Personal-Phone-Manager-10.8.1-Cross-Site-Scripting.html exploit vdb entry third party advisory

Frequently Asked Questions

What is the severity of CVE-2021-25680?
CVE-2021-25680 has been scored as a medium severity vulnerability.
How to fix CVE-2021-25680?
To fix CVE-2021-25680, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2021-25680 being actively exploited in the wild?
It is possible that CVE-2021-25680 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~2% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.